Published: March 2, 2026 at 1:47 pm
SkinBioTherapeutics plc has appointed an interim CEO for the next six months as its former leader is investigated over concerns that he misrepresented results.
Rachel Parsonage, who currently runs her own advisory consultancy, has agreed to take the role on a temporary basis after former CEO Stuart Ashman resigned recently.
Alyson Levett, who only joined the company’s board and as chair of its audit committee in January, is overseeing a ‘forensic’ investigation into the actions of Ashman.
The Newcastle firm’s share price fell from 19.5 pence to almost 5p after the news broke of the potential misrepresentation and Ashman’s immediate resignation.
However it has since recovered to 9p at the time of writing, helped by a 12.5% jump today following news of Parsonage’s appointment.